Propanc Biopharma Inc (NASDAQ:PPCB) rose 5.4% on Monday after announcing it has applied for a foreign filing license in Spain covering two new provisional patent applications.
The patents — which will be formally filed with IP Australia under Propanc’s wholly owned subsidiary, Propanc Pty Ltd — introduce novel approaches for treating therapy-resistant cancers and fibrosis. The discoveries stem from the company’s ongoing Joint Research and Drug Discovery collaboration with Spanish academic institutions.
One patent focuses on treating cancers that no longer respond to chemotherapy or radiotherapy. The second outlines formulations and methods aimed at addressing fibrosis, including organ-level fibrosis. Notably, this marks Propanc’s first patent describing use of its lead candidate, PRP, for chronic diseases outside oncology.
“The submission of these two patents represents a significant turning point for Propanc and the commercial potential of PRP for treating chronic diseases such as cancer and fibrosis,” said James Nathanielsz, Propanc’s Chief Executive Officer.
Propanc anticipates launching a Phase 1b First-In-Human trial in 2026 to establish the optimal therapeutic dose of PRP, laying the groundwork for subsequent Phase 2 studies evaluating the proenzyme therapy across multiple disease areas.